Ms. Sofia Wen, Founder & CEO of Shanghai Dunwill Medical Technology Development Company.

She has been committed to the cause of discovery, research & development, commercialization and clinical application of original biomarker diagnostic products since 2006.

Dr. David Peng holds a bachelor's degree in Biochemistry from Nankai University, and earned his Ph.D. in Molecular Biology from the University of Texas in the United States. Dr. Peng conducted postdoctoral research at the Genomics Institute of the Novartis Research Foundation (GNF).

Prior to joining Dunwill Medical, Dr. Peng worked as a senior scientist in the R&D department of Gen-Probe, and the chief scientist at Genoptix, a clinical laboratory of Novartis in the United States.

Since May 2013, Dr. Peng has served as the CTO of Dunwill Medical and manages the operation of the Genovo R&D center in the United States.

Dr. Peng has extensive experience in the development of molecular diagnostics assays and instruments. He has led the registration and commercialization of multiple molecular and cellular in vitro diagnostics assays and instruments through the US FDA and China NMPA regulation.

周闻先生在财务和资本市场方面有超20年的工作经验。

于2020年10月加入顿慧医疗任首席财务官。

周闻先生曾经总体负责如涵控股(Nasdaq: RUHN)和天华阳光(Nasdaq:SKYS)的成功上市。

周闻先生曾经普华永道中天会计师事务所担任高级经理，从事审计工作超过10年，负责多家企业的上市中的财务审计工作，如上海医药(02607)和中粮包装(00906)等